Kết quả tìm kiếm - Yen‐Yang Chen

  • Đang hiển thị 1 - 5 kết quả của 5
Tinh chỉnh kết quả
  1. 1
    Outcomes of Liposomal Irinotecan With 5‐FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status

    Outcomes of Liposomal Irinotecan With 5‐FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status Bằng Chieh-Ying Chang, Tai-Jan Chiu, Yen‐Yang Chen, Jen-Shi Chen, Wen-Chi Chou

    Được phát hành 2025
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study

    Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast canc... Bằng Kun-Ming Rau, Yung‐Chang Lin, Yen-Yang Chen, Jen‐Shi Chen, Kuan‐Der Lee, Cheng‐Hsu Wang, Hsien-Kun Chang

    Được phát hành 2015
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17

    A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17 Bằng Chun‐Nan Yeh, Ming‐Huang Chen, Yen‐Yang Chen, Ching‐Yao Yang, Chueh‐Chuan Yen, Chin‐Yuan Tzen, Li‐Tzong Chen, Jen‐Shi Chen

    Được phát hành 2017
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

    The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Bằng Jing‐Houng Wang, Yen‐Yang Chen, Kwong‐Ming Kee, Chih‐Chi Wang, Ming‐Chao Tsai, Yuan‐Hung Kuo, Chao‐Hung Hung, Weifeng Li, Hsiang‐Lan Lai, Yen‐Hao Chen

    Được phát hành 2022
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

    Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients... Bằng Hyun Cheol Chung, Yoon‐Koo Kang, Zhendong Chen, Yuxian Bai, Wan Zamaniah Wan Ishak, Byoung Yong Shim, Young Lee Park, Dong‐Hoe Koo, Jianwei Lu, Jianming Xu, Hong Jae Chon, Li‐Yuan Bai, Shan Zeng, Ying Yuan, Yen‐Yang Chen, Kangsheng Gu, Wen Yan Zhong, Shu Kuang, Chie‐Schin Shih, Shukui Qin

    Được phát hành 2021
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: